Premium
[O2–05–04]: IN COGNITIVELY NORMAL INDIVIDUALS, THE BEST CONCORDANCE BETWEEN CSF BIOMARKERS AND PET AMYLOID IS OBSERVED WITH THE COMBINATION OF B‐AMYLOID1–42 AND PHOSPHORYLATED TAU
Author(s) -
Lamari Foudil,
Epelbaum Stéphane,
Bertin Hugo,
Hampel Harald,
Bakardjian Hovagim,
Nyasse Francis,
Benyounes Imen,
Lista Simone,
Mestari Fouzi,
Jardel Claude,
Dubois Bruno,
Habert MarieOdile
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - French
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.170
Subject(s) - concordance , medicine , population , pathology , amyloid (mycology) , prospective cohort study , oncology , environmental health
O2-05-04 IN COGNITIVELY NORMAL INDIVIDUALS, THE BEST CONCORDANCE BETWEEN CSF BIOMARKERS AND PETAMYLOID IS OBSERVEDWITHTHECOMBINATIONOFBAMYLOID1-42ANDPHOSPHORYLATEDTAU Foudil Lamari, St ephane Epelbaum, Hugo Bertin, Harald Hampel, Hovagim Bakardjian Sr., Francis Nyasse, Imen Benyounes, Simone Lista, Fouzi Mestari, Claude Jardel, Bruno Dubois, Marie-Odile Habert, INSIGHT-preAD Study Group, AP-HP, UF Biochimie des Maladies Neuro-m etaboliques, Service de Biochimie M etabolique, Groupe Hospitalier Piti e-Salpêtri ere, Paris, France; Sorbonne University, UPMC, Paris, France; Sorbonne Universit es, Universit e Pierre et Marie Curie (UPMC) Paris 6, INSERM, CNRS, Institut du cerveau et de la moelle (ICM), D epartement de Neurologie, Institut de la M emoire et de la Maladie d’Alzheimer (IM2A), Hôpital Piti e-Salpêtri ere, Paris, France; Service de M edecine Nucl eaire, Hôpital de la Piti e-Salpêtri ere, AP-HP, Paris, France; CATI Multicenter Neuroimaging Platform, Paris, France; AXA Research Fund & UPMC Chair, Sorbonne Universit es, Universit e Pierre et Marie Curie (UPMC) Paris 06, INSERM, CNRS, Institut du Cerveau et de la Moelle (ICM), Institut de la M emoire et de la Maladie d’Alzheimer (IM2A), Paris, France; Institut de la M emoire et de la Maladie d’Alzheimer (IM2A), D epartement de Neurologie, Hôpital de la Piti e-Salpêtri ere, AP-HP, Paris, France; Sorbonne Universities, Universit e Pierre et Marie Curie-Paris 6, Paris, France; IHU-A-ICM Paris Institute of Translational Neurosciences, Hôpital Piti e-Salpêtri ere, Paris, France; ICM, Paris, France; IM2A Institute of Memory and Alzheimer’s Disease IHU-A-ICM Paris Institute of Translational Neurosciences Piti e-Salpêtri ere University Hospital, Paris, France; Institut de la M emoire et de la Maladie d’Alzheimer (IM2A), Paris, France; Pierre et Marie Curie, Paris, France; APHP-PITIE Salpetriere University Hospital, Paris, France; AXA Research Fund & UPMC Chair; Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Institute of Memory and Alzheimer’s Disease (IM2A) & Brain and Spine Institute (ICM)UMR S 1127, Hopital Piti e-Salpêtri ere, Paris, France; Sorbonne Universit es, Universit e Pierre et Marie Curie, Paris, France; APHP-PITIE Salpetriere University Hospital, Paris, France; Sorbonne University, UPMC, Paris, France; Sorbonne Universit es, Universit e Pierre et Marie Curie (UPMC) Paris 06, INSERM, CNRS, Institut du cerveau et de la moelle (ICM), Institut de la M emoire et de la Maladie d’Alzheimer (IM2A), Paris, France; Institut du Cerveau et de la Moelle Epini ere (ICM), Hôpital de la Piti e-Salpêtri ere, AP-HP, Paris, France; Institut de la M emoire et de la Maladie d’Alzheimer (IM2A), ICM, Hôpital de la Piti e-Salpêtri ere, AP-HP, Universit e Paris 6, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, INSERM U 1146, CNRS UMR 7371, Laboratoire d’Imagerie Biomedicale, Paris, France. Contact e-mail: stephane.epelbaum@aphp.fr